Cargando…
Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo
Impetigo is a contagious skin infection predominantly caused by Staphylococcus aureus. Decontamination of S. aureus from the skin is becoming more difficult because of the emergence of antibiotic-resistant strains. Bacteriophage endolysins are less likely to invoke resistance and can eliminate the t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784202/ https://www.ncbi.nlm.nih.gov/pubmed/31443379 http://dx.doi.org/10.3390/v11090769 |
_version_ | 1783457715607044096 |
---|---|
author | Imanishi, Ichiro Uchiyama, Jumpei Tsukui, Toshihiro Hisatsune, Junzo Ide, Kaori Matsuzaki, Shigenobu Sugai, Motoyuki Nishifuji, Koji |
author_facet | Imanishi, Ichiro Uchiyama, Jumpei Tsukui, Toshihiro Hisatsune, Junzo Ide, Kaori Matsuzaki, Shigenobu Sugai, Motoyuki Nishifuji, Koji |
author_sort | Imanishi, Ichiro |
collection | PubMed |
description | Impetigo is a contagious skin infection predominantly caused by Staphylococcus aureus. Decontamination of S. aureus from the skin is becoming more difficult because of the emergence of antibiotic-resistant strains. Bacteriophage endolysins are less likely to invoke resistance and can eliminate the target bacteria without disturbance of the normal microflora. In this study, we investigated the therapeutic potential of a recombinant endolysin derived from kayvirus S25-3 against staphylococcal impetigo in an experimental setting. First, the recombinant S25-3 endolysin required an incubation period of over 15 minutes to exhibit efficient bactericidal effects against S. aureus. Second, topical application of the recombinant S25-3 endolysin decreased the number of intraepidermal staphylococci and the size of pustules in an experimental mouse model of impetigo. Third, treatment with the recombinant S25-3 endolysin increased the diversity of the skin microbiota in the same mice. Finally, we revealed the genus-specific bacteriolytic effect of recombinant S25-3 endolysin against staphylococci, particularly S. aureus, among human skin commensal bacteria. Therefore, topical treatment with recombinant S25-3 endolysin can be a promising disease management procedure for staphylococcal impetigo by efficient bacteriolysis of S. aureus while improving the cutaneous bacterial microflora. |
format | Online Article Text |
id | pubmed-6784202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67842022019-10-16 Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo Imanishi, Ichiro Uchiyama, Jumpei Tsukui, Toshihiro Hisatsune, Junzo Ide, Kaori Matsuzaki, Shigenobu Sugai, Motoyuki Nishifuji, Koji Viruses Article Impetigo is a contagious skin infection predominantly caused by Staphylococcus aureus. Decontamination of S. aureus from the skin is becoming more difficult because of the emergence of antibiotic-resistant strains. Bacteriophage endolysins are less likely to invoke resistance and can eliminate the target bacteria without disturbance of the normal microflora. In this study, we investigated the therapeutic potential of a recombinant endolysin derived from kayvirus S25-3 against staphylococcal impetigo in an experimental setting. First, the recombinant S25-3 endolysin required an incubation period of over 15 minutes to exhibit efficient bactericidal effects against S. aureus. Second, topical application of the recombinant S25-3 endolysin decreased the number of intraepidermal staphylococci and the size of pustules in an experimental mouse model of impetigo. Third, treatment with the recombinant S25-3 endolysin increased the diversity of the skin microbiota in the same mice. Finally, we revealed the genus-specific bacteriolytic effect of recombinant S25-3 endolysin against staphylococci, particularly S. aureus, among human skin commensal bacteria. Therefore, topical treatment with recombinant S25-3 endolysin can be a promising disease management procedure for staphylococcal impetigo by efficient bacteriolysis of S. aureus while improving the cutaneous bacterial microflora. MDPI 2019-08-22 /pmc/articles/PMC6784202/ /pubmed/31443379 http://dx.doi.org/10.3390/v11090769 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Imanishi, Ichiro Uchiyama, Jumpei Tsukui, Toshihiro Hisatsune, Junzo Ide, Kaori Matsuzaki, Shigenobu Sugai, Motoyuki Nishifuji, Koji Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo |
title | Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo |
title_full | Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo |
title_fullStr | Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo |
title_full_unstemmed | Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo |
title_short | Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo |
title_sort | therapeutic potential of an endolysin derived from kayvirus s25-3 for staphylococcal impetigo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784202/ https://www.ncbi.nlm.nih.gov/pubmed/31443379 http://dx.doi.org/10.3390/v11090769 |
work_keys_str_mv | AT imanishiichiro therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo AT uchiyamajumpei therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo AT tsukuitoshihiro therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo AT hisatsunejunzo therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo AT idekaori therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo AT matsuzakishigenobu therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo AT sugaimotoyuki therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo AT nishifujikoji therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo |